Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Pharmos (PARS) -- Ignore unavailable to you. Want to Upgrade?

To: arnie h who wrote (158)	11/9/1998 8:00:00 PM
From: David Israel-Rosen	Respond to of 1386

The reality is that no one knows what Agis is doing here. One thing is for sure they are here to serve AGIS and that might include getting them into Biotech. Omer mentions Teva, if I recall, they were in generics for 50 years before they got into New Drugs. Why couldn't Agis do the same by merging with Pharmos. I think it is important for us to see thing for they are, not for what we want them to be Best Regards David

To: arnie h who wrote (158)	11/9/1998 8:02:00 PM
From: yosi s	Read Replies (3) \| Respond to of 1386

Let me reiterate my speculation regarding Agis. Agis bought into Pars. if this was for only investment ,then you buy under 5%. the difference between 5 and 5.2% is declaration. They got the attention of Aviv and I am sure contacts between Arkin and Aviv will follow.. This present new dynamics for both people. Agis a generic company, small enough not to be overwhelming. Yet to Pharmos they can bring certain expertise and financial stability. This can speed up future research. Enable to negotiate better with big Pharma. But what is most important it bring new dynamics into the picture. And the direction is seen by me to be positive .